EVEREST MED (01952) highlighted that as of 28 February 2026, the company’s authorized share capital remained at 500.00 million shares with a par value of USD0.0001, totaling USD50,000. The issued share capital stood at 353.58 million shares, an increase of 3,292 shares compared to the preceding month. Funds raised during the period from the exercised share options totaled HKD68,357.44.

According to the announcement, the company’s public float requirement remained in compliance. Under the share option plans, 158,573 shares maintained from its pre-IPO employee share option plan, 21.56 million shares were available from the post-IPO share option scheme, and 35.36 million shares were available under the newly adopted 2026 Share Scheme. The 2026 Share Scheme was approved on 24 February 2026, and no share awards have been granted under it. Meanwhile, 3.44 million shares remained available from the pre-IPO employee share option plan’s restricted stock units, and 1.61 million shares remained for awards granted under the post-IPO share award scheme. No treasury shares were involved during the month.